These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 36441966)
1. Strategies for Assessing Acceptable Intakes for Novel Ponting DJ; Dobo KL; Kenyon MO; Kalgutkar AS J Med Chem; 2022 Dec; 65(23):15584-15607. PubMed ID: 36441966 [TBL] [Abstract][Full Text] [Related]
2. Practical and Science-Based Strategy for Establishing Acceptable Intakes for Drug Product Dobo KL; Kenyon MO; Dirat O; Engel M; Fleetwood A; Martin M; Mattano S; Musso A; McWilliams JC; Papanikolaou A; Parris P; Whritenour J; Yu S; Kalgutkar AS Chem Res Toxicol; 2022 Mar; 35(3):475-489. PubMed ID: 35212515 [TBL] [Abstract][Full Text] [Related]
3. Acceptable intakes (AIs) for 11 small molecule N-nitrosamines (NAs). Bercu JP; Masuda-Herrera M; Trejo-Martin A; Sura P; Jolly R; Kenyon M; Thomas R; Ponting DJ; Snodin D; Tuschl G; Simon S; De Vlieger K; Hutchinson R; Czich A; Glowienke S; Reddy MV; Johanssen S; Vock E; Claude N; Weaver RJ Regul Toxicol Pharmacol; 2023 Aug; 142():105415. PubMed ID: 37257751 [TBL] [Abstract][Full Text] [Related]
4. A comprehensive review of sources of nitrosamine contamination of pharmaceutical substances and products. Akkaraju H; Tatia R; Mane SS; Khade AB; Dengale SJ Regul Toxicol Pharmacol; 2023 Mar; 139():105355. PubMed ID: 36792049 [TBL] [Abstract][Full Text] [Related]
5. Revisiting the Landscape of Potential Small and Drug Substance Related Nitrosamines in Pharmaceuticals. Burns MJ; Ponting DJ; Foster RS; Thornton BP; Romero NE; Smith GF; Ashworth IW; Teasdale A; Simon S; Schlingemann J J Pharm Sci; 2023 Dec; 112(12):3005-3011. PubMed ID: 37805074 [TBL] [Abstract][Full Text] [Related]
6. Computational Prediction of Metabolic α-Carbon Hydroxylation Potential of Chakravarti S Chem Res Toxicol; 2023 Jun; 36(6):959-970. PubMed ID: 37267457 [TBL] [Abstract][Full Text] [Related]
7. Determining recommended acceptable intake limits for N-nitrosamine impurities in pharmaceuticals: Development and application of the Carcinogenic Potency Categorization Approach (CPCA). Kruhlak NL; Schmidt M; Froetschl R; Graber S; Haas B; Horne I; Horne S; King ST; Koval IA; Kumaran G; Langenkamp A; McGovern TJ; Peryea T; Sanh A; Siqueira Ferreira A; van Aerts L; Vespa A; Whomsley R Regul Toxicol Pharmacol; 2024 Jun; 150():105640. PubMed ID: 38754805 [TBL] [Abstract][Full Text] [Related]
8. Maximizing use of existing carcinogenicity data to support acceptable intake levels for mutagenic impurities in pharmaceuticals: Learnings from N-nitrosamine case studies. Felter SP; Ponting DJ; Mudd AM; Thomas R; Oliveira AAF Regul Toxicol Pharmacol; 2023 Sep; 143():105459. PubMed ID: 37474097 [TBL] [Abstract][Full Text] [Related]
9. Are all nitrosamines concerning? A review of mutagenicity and carcinogenicity data. Thresher A; Foster R; Ponting DJ; Stalford SA; Tennant RE; Thomas R Regul Toxicol Pharmacol; 2020 Oct; 116():104749. PubMed ID: 32777431 [TBL] [Abstract][Full Text] [Related]
10. The Landscape of Potential Small and Drug Substance Related Nitrosamines in Pharmaceuticals. Schlingemann J; Burns MJ; Ponting DJ; Martins Avila C; Romero NE; Jaywant MA; Smith GF; Ashworth IW; Simon S; Saal C; Wilk A J Pharm Sci; 2023 May; 112(5):1287-1304. PubMed ID: 36402198 [TBL] [Abstract][Full Text] [Related]
11. Analysis of genotoxic N-nitrosamines in active pharmaceutical ingredients and market authorized products in low abundance by means of liquid chromatography - tandem mass spectrometry. Vogel M; Norwig J J Pharm Biomed Anal; 2022 Sep; 219():114910. PubMed ID: 35779354 [TBL] [Abstract][Full Text] [Related]
12. Nitrosamine acceptable intakes should consider variation in molecular weight: The implication of stoichiometric DNA damage. Fine J; Allain L; Schlingemann J; Ponting DJ; Thomas R; Johnson GE Regul Toxicol Pharmacol; 2023 Dec; 145():105505. PubMed ID: 37805106 [TBL] [Abstract][Full Text] [Related]
14. Nitrosamine Impurities in Herbal Formulations: A Review of Risks and Mitigation Strategies. Shekhar NR; Nagappan K; Singh MT; Dhanabal SP Drug Res (Stuttg); 2023 Oct; 73(8):431-440. PubMed ID: 37487523 [TBL] [Abstract][Full Text] [Related]
15. The derivation of nitrosamines from some therapeutic amines in the human environment. Akintonwa DA Ecotoxicol Environ Saf; 1985 Feb; 9(1):64-70. PubMed ID: 3987592 [TBL] [Abstract][Full Text] [Related]
17. Quantum chemical calculations of nitrosamine activation and deactivation pathways for carcinogenicity risk assessment. Göller AH; Johanssen S; Zalewski A; Ziegler V Front Pharmacol; 2024; 15():1415266. PubMed ID: 39086387 [TBL] [Abstract][Full Text] [Related]
18. Quantum Mechanical Assessment of Nitrosamine Potency. De S; Thapa B; Sayyed FB; Frank SA; Cornwell PD; Jolly RA Chem Res Toxicol; 2024 Jun; 37(6):1011-1022. PubMed ID: 38804898 [TBL] [Abstract][Full Text] [Related]
19. Approaches to cancer prevention based on an understanding of N-nitrosamine carcinogenesis. Hecht SS Proc Soc Exp Biol Med; 1997 Nov; 216(2):181-91. PubMed ID: 9349687 [TBL] [Abstract][Full Text] [Related]
20. Critical Analysis of Drug Product Recalls due to Nitrosamine Impurities. Bharate SS J Med Chem; 2021 Mar; 64(6):2923-2936. PubMed ID: 33706513 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]